What was the primary end point in the CREST multicenter randomized clinical trial?
The primary end point in the CREST multicenter randomized clinical trial was periprocedural stroke, death, or MI, plus later ipsilateral stroke, which occurred in 8.6% of patients undergoing CAS and 8.4% of patients undergoing CEA.